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Background.  The role of hepatitis C virus (HCV) coinfection and HCV-RNA in the development of diabetes mellitus (DM) 
in HIV-positive persons remains unclear.
Methods.  Poisson regression was used to compare incidence rates of DM (blood glucose >11.1 mmol/L, HbA1C >6.5% or 
>48 mmol/mol, starting antidiabetic medicine or physician reported date of DM onset) between current HIV/HCV groups (anti-
HCV-negative, spontaneously cleared HCV, chronic untreated HCV, successfully treated HCV, HCV-RNA-positive after HCV 
treatment).
Results.  A total of 16 099 persons were included; at baseline 10 091 (62.7%) were HCV-Ab-negative, 722 (4.5%) were sponta-
neous clearers, 3614 (22.4%) were chronically infected, 912 (5.7%) had been successfully treated, and 760 (4.7%) were HCV-RNA-
positive after treatment. During 136 084 person-years of follow-up (PYFU; median [interquartile range], 6.9 [3.6–13.2]), 1108 (6.9%) 
developed DM (crude incidence rate, 8.1/1000 PYFU; 95% CI, 7.7–8.6). After adjustment, there was no difference between the 5 
HCV strata in incidence of DM (global P = .33). Hypertension (22.2%; 95% CI, 17.5%–26.2%) and body mass index >25 (22.0%; 
95% CI, 10.4%–29.7%) had the largest population-attributable fractions for DM.
Conclusions.  HCV coinfection and HCV cure were not associated with DM in this large study. The biggest modifiable risk 
factors were hypertension and obesity, and continued efforts to manage such comorbidities should be prioritized.
Keywords.:  diabetes mellitus; direct-acting antivirals; hepatitis C; HIV; sustained virologic response.
Hepatitis C (HCV) monoinfection has been associated with 
an increased risk of a wide range of extrahepatic comorbidities 
[1], including cardiovascular disease and chronic kidney dis-
ease [2, 3], and has also been associated with higher mortality 
from cardiovascular disease, cancer, and renal disease [4, 5]. 
Most studies have reported an increased risk of diabetes mel-
litus (DM) in HCV-positive vs HCV-negative individuals, 
with a recent meta-analysis reporting a 1.6-fold increased 
odds [6]. However, a large French cohort study among HIV/
HCV-coinfected individuals found that DM was associated 
with cirrhosis but not HCV infection per se [7], while a large 
US study of HCV-monoinfected persons found that DM was 
associated with elevated Alanine Amino Transferase (ALT) 
and gamma glutamyl transpeptidase (GT), but not HCV itself 
[8]. The introduction of direct-acting antivirals (DAAs) for 
the treatment of HCV has had a major impact on HCV treat-
ment [9], with cure rates in excess of 90% in persons coinfected 
with both HIV and HCV [10]. Data from the pre-DAA era of 
interferon-based HCV therapy have indicated that sustained 
virologic response (SVR) could also have indirect beneficial ef-
fects in terms of improvements in lifestyle factors, a so-called 
epiphany effect [11], which could also potentially impact the 
risk for diabetes. In studies of persons coinfected with HCV and 
HIV, persons with SVR had a significantly lower incidence of 
DM compared with those treated for HCV without SVR [12]. 
A  lower incidence of DM among HCV treatment responders 
vs nonresponders was also found in a Spanish cohort of HIV/
HCV-coinfected persons [13]. Both previous studies were based 
on relatively few cases of DM and were conducted before the 
introduction of direct-acting antivirals, and therefore larger 
applyparastyle “fig//caption/p[1]” parastyle “FigCapt”
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studies with substantial follow-up and well-defined end points 
are required to further understand the role of HCV on the de-
velopment of DM in HIV-positive persons.
The aim of this study was therefore to investigate the inci-
dence of DM in a large pan-European cohort study according 
to HCV status in HIV-coinfected persons across 5 strata: 
anti-HCV-negative individuals, spontaneous HCV-RNA 
clearers, those with chronic untreated HCV infection, those 




Persons were included from the EuroSIDA study, a large pro-
spective observational cohort of almost 23 000 HIV-1-positive 
patients followed in 100 hospitals in 35 European countries plus 
Israel and Argentina. Individuals were enrolled into 10 cohorts 
from 1994 onward. In cohort 10, all HIV-positive patients were 
also required to be positive for anti-HCV antibodies (HCV-
RNA-positive, -negative, or unknown status). At recruitment, 
in addition to demographic and clinical data, a complete anti-
retroviral therapy history was obtained, together with the most 
recent CD4 cell counts and HIV-RNA measurements, as well 
as all HCV tests, HCV-RNA, HCV genotype, hepatitis B sur-
face antigen (HBsAg), and hepatitis B virus (HBV) DNA. Data 
are collected prospectively at clinical sites and sent to the co-
ordinating center at yearly intervals. At each follow-up visit, 
all CD4 cell counts, HIV-RNA, HCV tests, HCV-RNA, gen-
otype, and HBsAg results measured since last follow-up are 
collected, together with start and stop dates for antiretroviral 
drugs and HCV and HBV drugs. Detailed information about 
data collected in EuroSIDA can be found at http://www.chip.
dk/Ongoing-Studies/EuroSIDA/About.
Patient Consent Statement
Informed patient consent was obtained according to local and/or 
national ethics committee requirements; consent was obtained 
from each particpant before any study-related procedure was 
performed and in accordance with the International Conference 
on Harmonisation of Technical Requirements for Registration 
of Pharmaceuticals for Human Use (ICH) – Good Clinical 





DM was defined according to laboratory values (blood glu-
cose levels >11.1  mmol/L or HbA1C >6.5%/48  mmol/L) 
and/or use of antidiabetic medication. We used a blood glu-
cose >11.1  mmol/L to be conservative, reflecting missing in-
formation on whether glucose was measured in a fasting state 
or not. According to the EuroSIDA Manual of Operations, 
DM can be defined by sending the laboratory data, by the 
use of antidiabetic medication, or the site can report the clin-
ical diagnosis based on these criteria without sending labo-
ratory data (https://www.chip.dk/Portals/0/files/RESPOND/
RESPOND%20Manual%20of%20Operations%20MOOP__
Version%201.6.pdf?ver=2019-11-05-124535-643). Baseline was 
defined as the earliest date after cohort enrollment or January 
1, 2001 (when collection of prospective information on DM 
began), with known HCV serostatus and, for those who were 
anti-HCV-positive, known HCV-RNA status. Persons aged 
<18  years at baseline or without a CD4 count and HIV viral 
load in the 12 months before or 1 month after baseline were ex-
cluded, as were persons with DM before baseline.
Based on time-updated HCV antibody tests, HCV-RNA, and 
HCV treatment, we defined 5 HCV groups, as previously pub-
lished [14]:
 1. anti-HCV-negative;
 2. HCV antibody–positive, HCV-RNA-negative, untreated 
(spontaneous clearers);
 3. HCV antibody–positive, HCV-RNA-positive, untreated 
(chronic infections);
 4. HCV antibody–positive, HCV-RNA-negative, treated (suc-
cessfully treated with any HCV therapy; cured);
 5. HCV antibody–positive, HCV-RNA-positive, treated 
(treated, HCV-RNA positive).
These 5 strata were defined on the basis of latest anti-HCV 
test and HCV-RNA measurement. Those treated and HCV-
RNA-positive included persons who did not achieve SVR, per-
sons who were HCV-RNA-positive who had started treatment 
more recently, those reinfected with HCV, and persons without 
an HCV-RNA measurement after treatment completion and 
lacking an end-of-treatment response. Persons were followed 
until their last visit (median June 2018), date of death, or DM, 
whichever occurred first. Person-years of follow-up (PYFU) 
and DM events accrued according to current HCV stratum 
using the last observation carried forward, and persons could 
contribute PYFU to >1 stratum.
Statistical Analysis
Characteristics of patients were compared across strata using 
chi-square tests for categorical variables and the Kruskal-Wallis 
test for continuous data. Incidence rates of DM per 1000 PYFU 
were calculated within HCV groups, and Poisson regression 
was used to compare these rates with persons cured as the ref-
erence group. In addition to univariate analyses, we adjusted 
for all factors fixed at baseline (except HCV status) and all 
factors updated. Factors included were gender, HIV exposure 
group, region of Europe (North, Central West, South, Central 
East, East, and Argentina) [15], development of chronic kidney 
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disease [14], HIV viral load, prior AIDS, cumulative exposure 
to zidovudine, stavudine, and didanosine [16], cardiovascular 
disease, non-AIDS-defining malignancies (NADMs), end-stage 
liver disease (ESLD; ascites, hepatorenal syndrome, grade III/
IV hepatic encephalopathy, unspecified liver decompensa-
tion, esophageal variceal bleeding, spontaneous bacterial per-
itonitis, liver transplantation, and hepatocellular carcinoma; 
further information about these events is available at https://
www.chip.dk/Studies/EuroSIDA/Study-documents), smoking 
status (never smoked, current smoker, past smoker, unknown 
smoking status), hypertension [17], body mass index, CD4, 
nadir CD4, age, and baseline date. Liver fibrosis was defined 
according to our previous study [18]. In brief, data were avail-
able on all liver biopsy and Fibroscan test results performed at 
participating centers. Information on aspartate transaminase 
(AST) and platelet counts was used to calculate the AST-to-
platelet ratio (APRI). Hyaluronic acid was available for a small 
subset. The most recent fibrosis marker measured (before base-
line or time-updated) was used to define fibrosis stage, and 
where >1 marker was measured, priority was given to biopsy, 
Fibroscan, APRI, and hyaluronic acid. A priori, we investigated 
the interaction between age and HCV strata.
We performed a wide range of sensitivity analyses to inves-
tigate the robustness of our results to different assumptions. 
These included carrying the last HCV-RNA measurement for-
ward for a maximum of 12  months, excluding persons with 
stage F3/F4 liver fibrosis at baseline, excluding men who have 
sex with men (MSM) with a more recent HCV infection, and an 
analysis limited to post-2014, when DAAs became more widely 
available for persons included in the EuroSIDA study [19]. In 
addition, we investigated excluding centers in EuroSIDA where 
the 95% CI for the center did not include the population point 
estimate, as incidence of DM could depend on frequency of lab-
oratory testing within centers.
To address which risk factors have the strongest impact on the 
development of DM, we calculated the population-attributable 
risk fraction (PAF) for the key identified risk factors. PAF ex-
presses the proportion of events that could have been avoided 
had that risk factor not been present and considers both the 
strengths of the associations and the incidence rate of the 
risk factor.
All analyses were performed in SAS, version 9.4 (SAS 
Institute, Cary, NC, USA).
RESULTS
Of 22 828 persons enrolled in the EuroSIDA study, 3948 were 
excluded as their HCV status and/or HCV-RNA status was 
unknown, 754 were excluded with DM before the study base-
line, 1439 were excluded with no prospective follow-up, and 
588 were excluded with missing CD4 and/or HIV viral load at 
baseline. Compared with the 16 099 included in these analyses, 
the 2029 excluded due to no follow-up or missing CD4/viral 
loads were more likely to be females, be younger, have a prior 
AIDS diagnosis, have fibrosis stage F3/F4 at baseline, be from 
Central Eastern Europe, have an earlier baseline date, and be 
HBsAg-positive.
Characteristics of the 16 099 included individuals are shown 
in Table  1, stratified by HCV strata at baseline. The majority 
of those included were in group 1 at baseline (HCV-Ab nega-
tive; 10 091; 62.7%), followed by those in group 3 (chronically 
infected; n = 3614; 22.4%), with smaller numbers in group 2 
(spontaneous clearers; n = 722; 4.5%), group 4 (successfully 
treated; n = 912; 5.7%), and group 5 (treated, HCV-RNA pos-
itive; n = 760; 4.7%). The HCV strata were heterogeneous at 
baseline, with a lower burden of fibrosis and of comorbidities 
in group 1 (HCV-Ab negative) compared with other groups. 
The median baseline age (interquartile range [IQR]) was 41 
(35–49) years, the CD4 count (IQR) was 443/mm3 (288–633/
mm3), and the baseline date (IQR) was January 2006 (January 
2001–May 2012).
The median follow-up (IQR) was 6.9 (3.6–13.2) years per 
person. During 136 084 PYFU, 1108 developed DM, for an in-
cidence rate of 8.14/1000 PYFU (95% CI, 7.66–8.62). Of 1108 
persons with DM, 354 cases were defined using HbA1c, 628 
using glucose levels, 524 with a clinical diagnosis, and 521 based 
on use of antidiabetic medication. These figures include 225, 
176, and 114 persons who were diagnosed with DM using 2, 3, 
or 4 methods, respectively. The crude incidence of DM stratified 
by HCV strata is shown in Table 2. The crude incidence of DM 
was highest in persons who are HCV-Ab negative (8.66/1000 
PYFU; 95% CI, 8.08–9.25) and lowest in spontaneous clearers 
(5.62/1000 PYFU; 95% CI, 3.61–7.63). The incidence of DM in 
individuals who were chronically infected, successfully treated, 
and treated and HCV-RNA-positive was quite similar, at around 
7/1000 PYFU. In univariate analyses, there was no evidence of a 
difference in incidence of DM across the HCV strata compared 
with those who were successfully treated.
Association Between HCV Strata and Development of DM
After adjustment, there was no difference between the HCV 
strata and incidence of DM, as shown in Figure 1. In a model 
that allowed cofactors to be updated over time (Figure  1), 
those who were HCV-Ab-negative (adjusted incidence rate 
ratio [aIRR], 1.21; 95% CI, 0.88–1.66) and chronically infected 
(aIRR, 1.29; 95% CI, 0.94–1.77) had the highest incidence rates 
of DM compared with persons who had been cured, although 
the increased incidence was not statistically significant, and 
there was no evidence of an overall difference between strata 
(global P = .33). Highly consistent results were seen in a model 
where all cofactors except HCV strata were fixed at baseline, 
with no differences between HCV strata (global P = .68). 
Other factors associated with developing DM are summarized 
in Figure  1 and were consistent in both multivariate models. 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6 • ofid • Mocroft et al
The strongest factors associated with the development of DM 
were increasing age, development of cardiovascular disease 
(CVD), NADM, ESLD, hypertension, a high body mass index 
(BMI), and stage 4 liver fibrosis. There was a nonsignificantly 
increased incidence of DM associated with stage 2 (aIRR, 1.24; 
95% CI, 0.86–1.78) or stage 3 liver fibrosis (aIRR, 1.32; 95% 
CI, 0.85–2.06) compared with stage 0/1 after adjustment. Our 
results were consistent across all our sensitivity analyses, in-
cluding carrying the last HCV-RNA measurement forward for 
a maximum of 12 months, adjusting for starting integrase in-
hibitors, excluding MSM from analyses with more recent HCV 
infection, excluding persons with stage F3/F4 liver fibrosis at 
baseline, an analysis limited to post-2014, and excluding cen-
ters in EuroSIDA where the 95% CI for the center did not in-
clude the population point estimate (data not shown).
The association between HCV strata and DM differed 
for those aged ≤40 and those aged >40 (Pinteraction = .0060). 
This is summarized in Figure 2. In persons aged ≤40 years, 
those who were chronically infected had a similar inci-
dence of DM compared with those who had been cured 
(aIRR, 0.97; 95% CI, 0.59–1.60), while in persons aged 
>40, there was a significantly increased incidence of DM 
in those who were chronically infected compared with 
individuals who had been cured (aIRR, 1.51; 95% CI, 
1.01–2.26).
Population-Attributable Fractions for Modifiable and Nonmodifiable Risk 
Factors Associated With DM
The PAFs for key factors associated with DM are shown in 
Figure  3. The largest PAF was associated with development 
of hypertension, where an estimated 22.2% (95% CI, 17.5%–
26.2%) of DM diagnoses could have been avoided if persons 
were not hypertensive. A BMI of >25 contributed 22.0% of DM 
cases (95% CI, 10.4%–29.7%). Comorbidities, including AIDS, 
ESLD, NADM, CVD, and stage F4 liver fibrosis, all contributed 
small but significant PAFs of ~2%–5%. Aging, a nonmodifiable 
risk factor, also contributed large PAFs, particularly among 
those aged 40–60 years. PAFs for HCV strata were not calcu-
lated, as there was no evidence of an association between HCV 
strata and development of DM.
Restricting the PAF analysis to those with chronic HCV in-
fection and those treated for HCV (groups 3–5), the PAF for 
cirrhosis was 10.1% (95% CI, 6.2%–12.8%). The PAFs for the 
other factors were similar to the overall analysis except for a 
decreased contribution due to age >50  years (Supplementary 
Figure 1).
DISCUSSION
This large cohort study is one of the largest to date of HIV/
HCV-coinfected persons including >16  000 persons and 
136  000 PYFU. We found no difference in the rates of DM 
0.10 1.00 10.00
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• Group 1 (HCV-Ab negative)
• Group 2 (spontaneous clearers)
• Group 3 (chronically infected)
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Liver fibrosisa (F4 vs F0/F1)
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Figure 1.  Factors associated with incidence of diabetes mellitus. Adjusted for factors shown and gender, HIV transmission risk group, nadir CD4, baseline date, glucose 
and HbA1C levels (as fixed values at baseline), HBsAg, cumulative exposure to zidovudine, stavudine, and didanosine, HIV viral load, CD4, smoking, chronic kidney disease as 
time-updated. aIncluded as time-updated variables. DM was defined as either blood glucose >11.1 mmol/L, HbA1C >6.5%, or >48 mmol/mol, starting antidiabetic medicine, 
or physician-reported date of DM onset. Abbreviations: DM, diabetes mellitus; HCV, hepatitis C virus.



























1 2 3 4 5 1 2 3 4 5
HCV status HCV RNA HCV treatment Group description Group
Negative Negative N/A HCV-Ab-negative 1   
Positive Negative Untreated Spontaneous clearers 2
Positive Positive Untreated Chronically infected 3
Positive Negative Treated Successfully treated 4
Positive Positive Treated Treated; HCV-RNA-positive 5
Aged ≤ 40 Aged > 40
Figure 2.  Multivariate incidence rate ratios of diabetes mellitus: Stratification by age. Adjusted for factors shown and gender, ethnic origin, HIV transmission risk group, 
region, nadir CD4, baseline date, glucose and HbA1C levels (as fixed values at baseline), HBsAg, cumulative exposure to zidovudine, stavudine, and didanosine, HIV viral load, 
CD4, smoking, AIDS, cardiovascular disease, non-AIDS-defining malignancies, end-stage liver disease, hypertension, liver fibrosis, chronic kidney disease, and body mass 
index as time-updated. DM was defined as either blood glucose >11.1 mmol/L, HbA1C >6.5%, or >48 mmol/mol, starting antidiabetic medicine, or physician-reported date of 
DM onset. Abbreviations: DM, diabetes mellitus; HCV, hepatitis C virus.























Figure 3.  Population-attributable fractions for diabetes mellitus. Adjusted for gender, ethnic origin, HIV transmission risk group, region, nadir CD4, baseline date, 
glucose and HbA1C levels (as fixed values at baseline), HCV strata, HBsAg, cumulative exposure to zidovudine, stavudine, and didanosine, HIV viral load, CD4, smoking, 
AIDS, cardiovascular disease, non-AIDS-defining malignancies, end-stage liver disease, hypertension, liver fibrosis, chronic kidney disease, and body mass index as time-
updated. DM was defined as either blood glucose >11.1 mmol/L, HbA1C >6.5%, or >48 mmol/mol, starting antidiabetic medicine, or physician-reported date of DM onset. 
Abbreviations: DM, diabetes mellitus; HCV, hepatitis C virus; PAF, population-attributable fraction.
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between well-defined HCV strata including chronic and cured 
HCV. Traditional DM risk factors, such as age, hypertension, 
and obesity were much stronger predictive factors of DM than 
HCV status and whether someone with chronic HCV infection 
had been successfully treated.
We found no overall differences in the incidence of DM re-
garding the presence of replicating HCV infection across the 
HCV strata we included, and this was consistent across the dif-
ferent sensitivity analyses. Data from a smaller cohort study in-
cluding 95 DM cases in persons with and without SVR from 
Berenguer et al. found a ~50% reduction in DM in those with 
SVR compared with those without SVR after interferon (IFN) 
therapy [13]. Data from the Swiss HIV Cohort Study including 
~200 patients with DM found no increased incidence of DM 
comparing HCV-Ab-positive with HCV-Ab-negative individ-
uals, while a comparison of HCV-Ab-positive individuals with 
and without SVR after IFN therapy suggested a lower incidence 
of DM in those with SVR, albeit with very wide confidence 
intervals [12]. Possible reasons for the discrepancies include dif-
ferences in the populations included, that DM may develop over 
months or years with active HCV replication, and that a much 
longer follow-up period is required to observe differences, as 
well as differences in a study’s ability to adjust for important risk 
factors for DM, such as body mass index and hypertension, as 
we were able to in this analysis.
In a preplanned analysis, we found that the association be-
tween HCV strata and DM differed in those aged ≤40 compared 
with those aged >40 years. In persons aged >40 years, where the 
greatest burden from DM typically occurs, those with chronic 
untreated HCV had a significantly higher incidence of DM 
after adjustment compared with those who had been treated, 
regardless of whether the individual had cleared HCV-RNA or 
remained HCV-RNA-positive. Modifiable risk factors for DM, 
such as increasing weight and hypertension, should be closely 
monitored as persons age, and interventions should be targeted 
at those at greatest risk, such as those aged >40 years. The higher 
rate of DM in chronically infected persons aged >40 years may 
reflect a longer duration of HCV infection in older persons, 
which we were unable to adjust for. Our findings of lower rates 
of DM in individuals treated for HCV aged ≥40 years, regard-
less of response to treatment, could partly be explained by con-
founding by indication or more speculatively by improvement 
in lifestyle factors among those treated, described as either the 
“epiphany” effect [11] or the “Hawthorne” effect [20]. Further, 
DAA treatment in EuroSIDA began to increase most notably 
around 2015 [19]; before this, it is likely that the healthiest per-
sons with lower rates of advanced fibrosis/cirrhosis and those 
most likely to respond to treatment were selected for interferon 
and ribavirin treatment with its known toxicities and limited 
treatment responses [21]. This channeling bias might partly 
explain lower rates in those treated with pegylated interferon/
ribavirin than those with chronic untreated infection. Further 
studies focused on persons exposed to DAAs are needed to ex-
plore this association further.
Aging, hypertension, and obesity were all associated with the 
development of DM in our study, as previously reported and 
summarized by others [16, 22–24]. Smoking was not associated 
with development of DM, as previously reported by the D:A:D 
study [16]. We also found that HIV-associated comorbidities, 
including AIDS, non-AIDS-defining malignancies, and cardio-
vascular disease, were all associated with an increased incidence 
of DM. The association between incidence of DM and both ma-
lignancies and cardiovascular disease is likely to be explained 
by sharing risk factors. We have adjusted for some, such as BMI, 
hypertension, and aging, but there are likely to be other risk fac-
tors in common, such as physical inactivity and poor diet, that 
we were not able to adjust for [25]. While each of these HIV-
associated comorbidities was significantly associated with DM, 
the PAFs were small, indicating that although they were risk 
factors, their underlying prevalence was low.
Whereas we did not find an association between incidence of 
DM and HCV infection per se, both liver cirrhosis and ESLD 
were associated with increased incidence of DM. These findings 
indicate an indirect role of HCV in increasing the risk of DM 
and are in agreement with findings from another recent large 
French cohort study of HIV/HCV-coinfected persons [7]. The 
liver plays a central role in the homeostasis of blood glucose 
levels through glycogenolysis and gluconeogenesis, although 
an impairment severe enough to translate into diabetes could 
probably only be seen in advanced or late-stage HCV-induced 
liver disease. The exact mechanisms through which liver cir-
rhosis can lead to DM are not well defined, but there is growing 
evidence that both insulin resistance and β-cell dysfunction 
contribute [26]. Even with a positive association with liver fi-
brosis and ESLD, the PAF was small due to the comparatively 
low prevalence of F4 fibrosis and ESLD among our population. 
In an analysis restricted to those with either chronic HCV in-
fection or treated HCV infection, the PAF due to cirrhosis was 
10%, with lifestyle factors such as increased BMI and hyper-
tension being more important. Despite the comparatively low 
PAF due to cirrhosis, it remains important to diagnose and treat 
HCV early to reduce the risk of DM and other complications, as 
well as to achieve the global elimination of HCV [27]. Among 
the modifiable risk factors, hypertension and obesity were as-
sociated with the largest PAFs in our population. Traditional 
interventions used to reduce such risk factors in the general 
population may need modification to improve outcomes in 
adults with HIV in order to have a substantial impact [28]. Our 
results do, however, highlight the role of traditional risk factors 
for DM and the importance of screening and managing such 
risk factors.
The limitations of this study should be noted. We are not 
able to distinguish between type 1 and type 2 DM and used a 
variety of measures to define DM, reflecting heterogeneity in 
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data collected across Europe. We focused our analyses on DM 
and have no data on insulin resistance, which may be associ-
ated with HCV and precede DM [29], possibly due to impaired 
pancreatic beta cells in HCV-positive individuals [30]. We have 
no information on duration of HCV infection and used the last 
HCV-RNA carried forward in our analysis. Where this was neg-
ative after HCV treatment we assumed SVR, consistent with our 
previous work [14]. As with many observational studies, our 
inclusion and exclusion criteria for these analyses excluded a 
significant proportion of persons, and there was variability in 
completeness of data. Using time-updated analyses and last ob-
servation carried forward includes data measured after baseline; 
for example, the proportion with missing data on fibrosis stage 
declined to 12.7% over time, of which the majority of missing 
data (88.8%) was among those who were anti-HCV-negative. 
Despite these limitations, our results were consistent across all 
our sensitivity analyses. We were not able to specifically address 
the role of DAAs in our HCV-treated groups due to limited fol-
low-up after DAA initiation. The strength of our study is that it 
is one of the largest of coinfected persons reported to date, with 
an extensive quality assurance and data monitoring program.
In conclusion, HCV coinfection and cure of chronic HCV, 
mainly with DAAs, were not associated with the development 
of DM in this large cohort study, and there were few differences 
in DM across the 5 well-defined HCV strata included in this 
large study. The biggest modifiable risk factors of DM were hy-
pertension and obesity, and continued efforts to manage such 
comorbidities should be prioritized.
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